Despite significant advances over the past decades of research, pancreatic cancer (PC)
continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the
most potent professional antigen-presenting cells and are involved in the induction and
regulation of antitumor immune responses. DC-based immunotherapy has been used in
clinical trials for PC. Although safety, efficacy, and immune activation were reported in
patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for …